Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Tricida, Inc.
  6. Summary
    TCDA   US89610F1012

TRICIDA, INC.

(TCDA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/11/2021 06/14/2021 06/15/2021 06/16/2021 06/17/2021 Date
4.91(c) 5.35(c) 5.11(c) 4.95(c) 4.94 Last
139 366 662 686 483 485 184 671 182 509 Volume
-0.20% +8.96% -4.49% -3.13% -0.20% Change
More quotes
Financials (USD)
Sales 2021 - - -
Net income 2021 -184 M - -
Net Debt 2021 23,0 M - -
P/E ratio 2021 -1,55x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -187 M - -
Net Debt 2022 154 M - -
P/E ratio 2022 -1,74x
Yield 2022 -
Capitalization 249 M 249 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 64
Free-Float 97,3%
More Financials
Company
Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts... 
More about the company
Ratings of Tricida, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about TRICIDA, INC.
06/15TRICIDA, INC.  : Submission of Matters to a Vote of Security Holders, Financial ..
AQ
06/03SHAREHOLDER ALERT : Robbins LLP is Investigating Tricida, Inc. (TCDA) for Shareh..
BU
06/02Tricida to Present at the Goldman Sachs 42nd Annual Global Healthcare Confere..
GL
05/07TRICIDA  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
05/06CORRECTING and REPLACING -- Tricida Announces First Quarter 2021 Financial Re..
GL
05/06TRICIDA, INC.  : Results of Operations and Financial Condition (form 8-K)
AQ
05/06Tricida Announces First Quarter 2021 Financial Results
GL
04/27Tricida to Report First Quarter Financial Results and Host Conference Call an..
GL
04/16TRICIDIA INVESTIGATION INITIATED BY : Kahn Swick & Foti, LLC Investigates the O..
BU
04/08Tricida to Present at the Needham Virtual Healthcare Conference
GL
04/08TRICIDA  : to Present at the Needham Virtual Healthcare Conference
AQ
04/05TRICIDA  : Announces Multiple Data Presentations to Be Given at the Virtual Nati..
AQ
04/01TRICIDA, INC.  : Entry into a Material Definitive Agreement (form 8-K)
AQ
03/16TRICIDA, INC.  : Termination of a Material Definitive Agreement (form 8-K)
AQ
03/08TCDA FILING DEADLINE TODAY : Bernstein Liebhard LLP Reminds Investors of the Dea..
PR
More news
News in other languages on TRICIDA, INC.

- No features available -

More news
Chart TRICIDA, INC.
Duration : Period :
Tricida, Inc. Technical Analysis Chart | TCDA | US89610F1012 | MarketScreener
Technical analysis trends TRICIDA, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 15,00 $
Last Close Price 4,95 $
Spread / Highest target 304%
Spread / Average Target 203%
Spread / Lowest Target 1,01%
EPS Revisions
Managers and Directors
NameTitle
Gerrit Klaerner President, Chief Executive Officer & Director
Geoffrey M. Parker Executive VP, Chief Operating & Financial Officer
Klaus R. Veitinger Chairman
Wilhelm Stahl Chief Technology Officer & Executive VP
Dawn Parsell Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
TRICIDA, INC.-29.79%249
MODERNA, INC.89.37%79 438
LONZA GROUP AG17.02%54 990
IQVIA HOLDINGS INC.36.31%46 809
CELLTRION, INC.-25.07%33 149
SEAGEN INC.-13.60%27 461